OXER1, a G protein-coupled oxoeicosatetraenoid receptor, mediates the survival-promoting effects of arachidonate 5-lipoxygenase in prostate cancer cells

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 185-195

  Sarveswaran, Sivalokanathan ^a   Ghosh, Jagadananda ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

5 Lipoxygenase; 5 OxoETE; Apoptosis; OXER1; PKC epsilon; PLC beta

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 5 OXOEICOSATETRAENOIC ACID RECEPTOR 1; ARACHIDONATE 5 LIPOXYGENASE; DIACYLGLYCEROL; MESSENGER RNA; PHOSPHOLIPASE C BETA; PROTEIN KINASE C EPSILON; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

5 OXOEICOSATETRAENOIC ACID RECEPTOR 1 GENE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATOR GENE; SIGNAL TRANSDUCTION;

APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; CELL LINE, TUMOR; CELL SURVIVAL; ESTRENES; HUMANS; MALE; PHOSPHOLIPASE C BETA; PROSTATIC NEOPLASMS; PROTEIN KINASE C-EPSILON; PYRROLIDINONES; RECEPTORS, EICOSANOID; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84878982887     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.027     Document Type: Article

References (52)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Fleshner N., Bagnell P.S., Klotz L., Venkateswaran V. Dietary fat and prostate cancer. J. Urol. 2004, 171:19-24.
3. Kolonel L.N., Nomura A.N., Cooney R.V. Dietary fat and prostate cancer: current status. J. Natl. Cancer Inst. 1999, 91:414-428.
4. Wang Y., Corr J.G., Thaler H.T., Tao Y., Fair W.R., Heston W.D. Decreased growth of established prostate LNCaP tumors in nude mice fed a low-fat diet. J. Natl. Cancer Inst. 1995, 87:1456-1462.
5. West D.W., Slattery M.L., Robison L.M., French T.K., Mahoney A.W. Adult dietary intake and prostate cancer risk in Utah: a case control study with special emphasis on aggressive tumors. Cancer Causes Control 1991, 2:85-94.
6. Giovannucci E.L., Rimm E.B., Colditz G.A., Stampfer M.J., Ascherio A., Chute C., Willett W.C. A prospective study of dietary fat and risk of prostate cancer. J. Natl. Cancer Inst. 1993, 85:1571-1579.
7. Gann P.H., Hennekens C.H., Sacks F.M., Grodstein F., Giovannucci E.L., Stampfer M.J. Prospective study of plasma fatty acids and risk of prostate cancer. J. Natl. Cancer Inst. 1994, 86:281-286.
8. Ghosh J., Myers C.E. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res. Commun. 1997, 235:418-423.
9. Ghosh J., Myers C.E. Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv. Exp. Med. Biol. 1999, 469:577-582.
10. Anderson K.M., Seed T., Vos M., Mulshine J., Meng J., Alrefai W., Ou D., Harris J.E. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 1998, 37:161-173.
11. Ghosh J., Myers C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95:13182-13187.
12. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
13. Balmanno K., Cook C.J. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009, 16:368-377.
14. Basu A., Sivaprasad U. Protein kinase Cε makes the life and death decision. Cell. Signal. 2007, 19:1633-1642.
15. Sarveswaran S., Myers C.E., Ghosh J. MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase. Cancer Lett. 2010, 291:167-176.
16. Sarveswaran S., Thamilselvan V., Brodie C., Ghosh J. Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. Biochimica et Biophysica Acta 1813, 2011:2108-2117.
17. Sivaprasad U., Shankar E., Basu A. Downregulation of Bid is associated with PKCepsilon-mediated TRAIL resistance. Cell Death Differ. 2007, 14:851-860.
18. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995, 9:484-496.
19. Mellor H., Parker P.J. The extended protein kinase C superfamily. Biochem. J. 1998, 332:281-292.
20. Gavrielides M.V., Frijhoff A.F., Conti C.J., Kazanietz M.G. Protein kinase C and prostate carcinogenesis: targeting the cell cycle and apoptotic mechanisms. Curr. Drug Targets 2004, 5(2004):431-443.
21. McJilton M.A., Sikes C.V., Wescott G.G., Wu D., Foreman T.L., Gregory C.W., Weidner D.A., Ford O.H., Lasater A.M., Mohler J.L., Terrian D.M. Protein kinase Cε interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 2003, 22:7958-7968.
22. Wang D., DuBois R.N. Eicosanoids and cancer. Nature Rev. Cancer 2010, 10:181-193.
23. Ghosh J. Targeting 5-lipoxygenase for prevention and treatment of cancer. Curr. Enzyme Inhib. 2008, 4:18-28.
24. Gonzalez-Periz A., Claria J. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways. Curr. Top. Med. Chem. 2007, 7:297-309.
25. Wymann M.P., Schneiter R. Lipid signalling in disease. Nature Rev. Mol. Cell. Biol. 2008, 9:162-176.
26. Gupta S., Srivastava M., Ahmad N., Sakamoto K., Bostwick D.G., Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001, 91:737-743.
27. Powell W.S., Gravel S., MacLeod R.J., Mills E., Hashefi M. Stimulation of human neutrophils by 5-oxo-6,8,11,14-eicosatetraenoic acid by a mechanism independent of the leukotriene B4 receptor. J. Biol. Chem. 1993, 268:9280-9286.
28. O'Flaherty J.T., Taylor J.S., Kuroki M. The coupling of 5-oxo-eicosanoid receptors to heterotrimeric G proteins. J. Immunol. 2000, 164:3345-3352.
29. Hosoi T., Koguchi Y., Sugikawa E., Chikada A., Ogawa K., Tsuda N., Suto N., Tsunoda S., Taniguchi T., Ohnuki T. Identification of a novel human eicosanoid receptor coupled to G(i/o). J. Biol. Chem. 2002, 277:31459-31465.
30. Jones C.E., Holden S., Tenaillon L., Bhatia U., Seuwen K., Tranter P., Turner J., Kettle R., Bouhelal R., Charlton S., Nirmala N.R., Jarai G., Finan P. Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. Mol. Pharmacol. 2003, 63:471-477.
31. Hosoi T., Sugikawa E., Chikada A., Koguchi Y., Ohnuki T. TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis. Biochem. Biophys. Res. Commun. 2005, 334:987-995.
32. Brink C., Dahlen S., Drazen J., Evans J.F., Hay D.W., Rovati G.E., Serhan C.N., Shimizu T., Yokomizo T. International union of pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol. Rev. 2004, 56:149-157.
33. Sundaram S., Ghosh J. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochem. Biophys. Res. Commun. 2006, 339:93-98.
34. Moretti R.M., Montagnani M.M., Sala A., Motta M., Limonta P. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int. J. Cancer 2004, 112:87-93.
35. Yang P., Collin P., Madden T., Sweeney-Gotsch B., McConkey D., Newman R.A. Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase. Prostate 2003, 55:281-291.
36. Pham H., Vang K., Ziboh V.A. Dietary gamma-linolenate attenuates tumor growth in a rodent model of prostatic adenocarcinoma via suppression of elevated generation of PGE(2) and 5S-HETE. Prostagland. Leukotr. Ess. 2006, 74:271-282.
37. Carson J.P., Kulik G., Weber M.J. Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein kinase B. Cancer Res. 1999, 59:1449-1453.
38. Griner E.M., Kazanietz M.G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 2007, 7:281-294.
39. Steinberg R., Harari O.A., Lidington E.A., Boyle J.J., Nohadani M., Samare A.M., Ohba M., Haskard D.O., Mason J.C. A protein kinase Cepsilon-anti-apoptotic kinase signaling complex protects human vascular endothelial cells against apoptosis through induction of Bcl-2. J. Biol. Chem. 2007, 282:32288-32297.
40. Stahelin R.V., Digman M.A., Medkova M., Ananthanarayanan B., Melowic H.R., Rafter J.D., Cho W. Diacylglycerol-induced membrane targeting and activation of protein kinase cepsilon: mechanistic differences between protein kinases cdelta and cepsilon. J. Biol. Chem. 2005, 280:19784-19793.
41. Singer W.D., Brown H.A., Sternweis P.C. Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. Annu. Rev. Biochem. 1997, 66:475-509.
42. Noh D.Y., Shin S.H., Rhee S.G. Phosphoinositide-specific phospholipase C and mitogenic signaling. Biochim. Biophys. Acta 1995, 1242:99-113.
43. Aziz M.H., Manoharan H.T., Church D.R., Dreckschmidt N.E., Zhong W., Oberley T.D., Wilding G., Verm A.K. Protein kinase C-ε interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3-Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res. 2007, 67:8828-8838.
44. Brodie C., Bogi K., Acs P., Lazarovici P., Petrovics G., Anderson W.B., Blumberg P.M. Protein kinase C-epsilon plays a role in neurite outgrowth in response to epidermal growth factor and nerve growth factor in PC12 cells. Cell Growth Differ. 1999, 10:183-191.
45. Cacace A.M., Ueffing M., Philipp A., Han E.K., Kolch W., Weinstein I.B. PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. Oncogene 1996, 13:2517-2526.
46. Perletti G.P., Concari P., Brusaferri S., Marras E., Piccinini F., Tashjian A.H. Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway. Oncogene 1998, 16:3345-3348.
47. Felber M., Sonnemann J., Beck J.F. Inhibition of novel protein kinase C-epsilon augments TRAIL-induced cell death in A549 lung cancer cells. Pathol. Oncol. Res. 2007, 13:295-301.
48. Gorin M.A., Pan Q. Protein kinase Cε: an oncogene and emerging tumor biomarker. Mol. Cancer 2009, 8:9.
49. Werz O. 5-Lipoxygenase: cellular biology and molecular pharmacology. Curr. Drug Targets - Inflamm. Allergy 2002, 1:23-44.
50. Moody T.W., Leyton J., Martinez A., Hong S., Malkinson A., Mulshine J.L. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp. Lung Res. 1998, 24:617-628.
51. Hennig R., Ding X.Z., Tong W.G., Schneider M.B., Standop J., Friess H., Buchler M.W., Pour P.M., Adrian T.E. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. 2002, 161:421-428.
52. Lim J.Y., Oh J.H., Jung J.R., Kim S.M., Ryu C.H., Kim H.T., Jeun S.S. MK886-induced apoptosis depends on the 5-LO expression level in human malignant glioma cells. J. Neurooncol. 2010, 97:339-346.